Watertown, United States
Retex Pharmaceuticals, founded in 2022, is an innovative player in the Health Care and Pharmaceutical industries based in the United States. The company is addressing the significant need for novel medicines for chronic diseases by specifically targeting ion channels and GPCRs. This approach positions Retex at the forefront of pharmaceutical research, as they tackle complex biological processes to develop advanced therapeutic solutions.
Most recently, Retex Pharmaceuticals secured a Seed Round investment on 01 January 2024, granting them the financial foundation to advance their research programs. The funding was notably backed by LiquidMetal Ventures and 观正资本, indicating strong investor confidence in the company's potential within this high-impact sector. These strategic financial partnerships enhance Retex's prospects for growth and its mission to deliver transformative therapies in the healthcare landscape.
